menu
    • menu

    Company profile for Cohance Lifesciences

    Cohance Lifesciences-PSE
    News
    Cohance Lifesciences to sell CR Bio assets to Chromo Laboratories

    23 Jun 2025

    // INDPHARMAPOST

    Suven Pharmaceuticals is now Cohance Lifesciences

    09 May 2025

    // INDPHARMAPOST

    Suven Pharma Sets May 1 As Effective Date For Cohance Merger

    25 Apr 2025

    // PRESS RELEASE

    DATA COMPILATION
    #PharmaFlow

    Cohance Lifesciences

    Contact Supplier

    Website

    BIO Asia-Taiwan

    Not Confirmed

    Book a meeting

    envelop Contact Supplier

    Latest Content

    https://www.pharmacompass.com/video-supplier-spotlight/cohance-lifesciences/leading-cdmo-api-platform

    EVENTS

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INTERMEDIATES

    Key Products KEY PRODUCTS

    SERVICES

    Key Products KEY SERVICES

    INSPECTIONS & REGISTRATIONS

    PharmaCompass

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Related CompaniesRelated Companies

    About

    Cohance Lifesciences is a leading CDMO and API platform, offering products and services across all phases of a molecule’s lifecycle from development to commercialzation. With our expertise in complex chemistries, we provide end-to-end CDMO services to global innovators and have delivered numerous projects from concept to commercialization over the years.As a global API player, we serve customers across nearly 60 countries with 80+ molecules backed by robust R&D, regulatory capabilities and manufacturing infrastructure. We are among the top backward integrated exporters of pellets and have strong development and manufacturing capabilities.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Cohance Lifesciencesindia-flag Flag
    Country
    Country
    India
    Address
    Address
    202, 2nd Floor, B-Wing, Galaxy by Aurobindo Realty, Sy No 83/1, Hyderabad Know...
    Telephone
    Telephone
    +91 4044758595
    Client Email
    Email
    enquiries@cohance.com
    Client Website
    Website
    https://cohance.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/cohance-lifesciences/
    youtube
    YouTube
    Twitter
    Twitter
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    CPhI Korea

    Not Confirmed

    envelop Contact Supplier

    CPhI Korea

    Post an Enquiry

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    VLOG #PharmaReel

    read-more

    ReelPharmaLeading CDMO & API PlatformLeading CDMO & API Platform

    Leading CDMO & API Platform
    Leading CDMO & API Platform

    reelLeading CDMO & API Platform

    Your premier partner for end-to-end CDMO and API solutions, Cohance delivers excellence from concept and lab to global supply.

    Impressions: 626

    read-more

    CORPORATE CONTENT #SupplierSpotlight

    Product List 2025

    read-more

      https://www.pharmacompass.com/pdf/party/content/cohance-lifesciences-party-content-46875.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Corporate Presentation

    read-more

      https://www.pharmacompass.com/pdf/party/content/cohance-lifesciences-party-content-62354.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    GMP Certificate 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/cohance-lifesciences-party-content-14233.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    FDF Product List 2025

    read-more

      https://www.pharmacompass.com/pdf/party/content/cohance-lifesciences-party-content-72325.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    API Product List 2025

    read-more

      https://www.pharmacompass.com/pdf/party/content/cohance-lifesciences-party-content-28247.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Intermediate Product List 2025

    read-more

      https://www.pharmacompass.com/pdf/party/content/cohance-lifesciences-party-content-82565.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Pellet Product List 2025

    read-more

      https://www.pharmacompass.com/pdf/party/content/cohance-lifesciences-party-content-91080.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    Antibody-Drug Conjugate Brochure 2024

    read-more

      https://www.pharmacompass.com/pdf/party/content/cohance-lifesciences-party-content-26405.pdf

      Open PDFOpen PDF
      UploadUpload
      Key ShareShare

    DATA COMPILATION #PharmaFlow

    read-more
    read-more
    CDMO Activity Tracker: Veranova, Carbogen lead ADC investments; Axplora, Polfa Tarchomin, Famar expand European footprint

    CDMO Activity Tracker: Veranova, Carbogen lead ADC investments; Axplora, Polfa Tarchomin, Famar expand European footprint

    During the second quarter (Q2) of 2025, contract development and manufacturing organizations (CDMOs) made substantial investments in specialized therapeutic manufacturing. The quarter also saw CDMOs pursue high-value, complex manufacturing niches, particularly in antibody-drug conjugates (ADCs), cell and gene therapies (CGTs) and oligonucleotides.Alongside these trends, Q2 also saw CDMOs strengthen their footprint in the United States amid concerns over rising tariffs and unpredictable trade policies being enforced by the Trump administration.Regeneron Pharmaceuticals committed over US$ 3 billion through a 10-year agreement with Fujifilm Diosynth Biotechnologies to nearly double its US manufacturing capacity for biologics. Under this agreement, Fujifilm will manufacture and supply drug products for Regeneron at its large-scale facility in Holly Springs, North Carolina.Thermo Fisher Scientific announced plans to invest an additional US$ 2 billion in the US over four years, reinforcing its manufacturing and R&D capabilities. With 64 facilities spread across 37 states, Thermo Fisher aims to bolster American innovation and competitiveness. Similarly, Piramal Pharma announced a US$ 90 million investment plan for expanding two facilities in the US, thereby bringing its total investment in the country to US$ 570 million. View CDMO Activity Tracker for Q2 2025 (Free Excel Available)Veranova, Carbogen lead ADC wave; Axplora doubles down on HPAPI production in ItalyThe quarter saw substantial investments in ADC manufacturing. Veranova announced a US$ 20 million investment in bioconjugation development and cGMP manufacturing capacity at its Devens, Massachusetts campus. With this investment, Veranova will be able to provide a more comprehensive suite of services to its partners developing ADCs and other bioconjugates. Veranova’s total investment in the Devens facility now stands at over US$ 50 million. Swiss CDMO Carbogen announced a US$ 31 million co-investment with an unnamed Japanese investor to expand its capabilities across its Aarau and Neuland (Switzerland) facilities. The facility will address increasing demand for complex and high-value compounds such as ADC drug linkers.Axplora announced a further €35 million (US$ 41 million) expansion of its Farmabios site in Italy, doubling the facility to approximately 108,000 square meters by mid-2026. This investment raises its total spend on the site to over €80 million (US$ 94.05 million) since 2019, supporting the production of highly potent active pharmaceutical ingredients (HPAPIs). Farmabios now stands as a key hub in Axplora’s global CDMO network.Polish pharmaceutical manufacturer Polfa Tarchomin is positioning itself as a significant player in the European CDMO market through its investment in the Center for Development and Production of Highly Potent Drugs. This 12,000 square meter facility has two state-of-the-art production lines designed for filling vials and pre-filled syringes with an annual capacity of 26 million product units.Skyepharma’s projected annual revenues from oncology-linked activities touched €10 million (US$ 11.2 million). The CDMO’s facility in Saint-Quentin-Fallavier is equipped to handle cytotoxic and cytostatic compounds, and is one of the few facilities in France capable of managing HPAPIs for oral anticancer treatments. View CDMO Activity Tracker for Q2 2025 (Free Excel Available) Athena acquires Medipha Santé, Famar buys MiP Pharma’s German site to strengthen European footprintDuring the quarter, several CDMOs enhanced their strategic capabilities through M&As. Athena Pharmaceutiques acquired  Medipha Santé to build a fully integrated pharmaceutical services platform in Europe. Based in Paris, Athena has strengthened its commercial and regulatory toolbox by bringing aboard Medipha Santé’s 35-strong team, which supports over 100 partner organizations and files approximately 350 dossiers annually with ANSM and other European agencies. With this integration, Athena positions itself as a one-stop CDMO partner.With the acquisition of MiP Pharma’s sterile manufacturing site in Homburg, Germany, the Famar Group has expanded its capabilities in aseptic and lyophilized fill-and-finish operations. The acquisition has strengthened Famar’s position in sterile drug manufacturing. The CDMO now has seven manufacturing facilities in Europe.PCI Pharma Services’ acquisition of Ajinomoto Althea has established a world-class, large-scale manufacturing hub in the San Diego region with state-of-the-art aseptic facilities for prefilled syringes, cartridges and high-potent formulations such as ADCs. PCI Pharma is now amongst the few US-based CDMOs capable of comprehensive ADC manufacturing.Samsung Biologics’ strategic spinoff of its biosimilar business stood out as a significant corporate restructuring exercise during the quarter. The separation of Samsung Bioepis, tentatively renamed Samsung Epis Holdings, aims to enhance Samsung Biologics’ strategic focus and build client trust, as it eliminates potential conflicts between CDMO services and proprietary drug development. The move came after Samsung Biologics inked a contract worth 737.3 billion Korean won (US$ 518 million) with an undisclosed US pharmaceutical company.WuXi Biologics announced a US$ 167 million divestment of its German facility to Terumo and broke ground on a microbial production plant in China. National Resilience, which was launched five years ago as the US drug manufacturer dedicated to broadening access to medicines and protecting biopharma supply chains, said it is shuttering six of its 10 facilities. The company said the sites were “not being fully utilized.” View CDMO Activity Tracker for Q2 2025 (Free Excel Available) MilliporeSigma, Simtra form 5-year ADC alliance; Silexion partners Catalent for siRNA developmentMerck KGaA’s MilliporeSigma and Simtra struck a five-year strategic alliance, combining expertise across the ADC value chain to reduce development timelines and complexity for biopharmaceutical companies. Viralgen collaborated with Trogenix to rapidly scale product supply for TGX-007, an AAV gene therapy for glioblastoma (a type of cancer of the brain and spinal cord).  Silexion announced a collaboration with Catalent for small interfacing RNA (siRNA) development and manufacturing. Catalent’s Limoges (France) facility will conduct formulation development and clinical manufacturing for Silexion’s SIL204 candidate, supporting both systemic and intra-tumoral delivery formulations.Skyepharma’s collaboration with Eneapharm through the Skyehub platform aims to support the treatment of patients suffering from exocrine pancreatic insufficiency, including those affected by cystic fibrosis or pancreatic cancer. Orion Corporation reached an agreement with Shilpa Biocare for the distribution of recombinant human albumin in Europe.Meanwhile, Aenova announced the launch of its Aenovation program, an initiative designed to fast-track early development of pharmaceutical formulations. The program addresses the critical challenges of bioavailability and time-to-market faced by poorly soluble drug candidates. View CDMO Activity Tracker for Q2 2025 (Free Excel Available) Our view The quarter saw CDMO developments mimic the broader trends in the pharmaceutical industry, such as onshoring of critical manufacturing capabilities in the US, consolidation of specialized expertise through strategic partnerships, and the relentless focus on emerging therapeutic modalities that promise to transform patient care. With CDMOs continuing to invest in next-generation manufacturing capabilities, we expect the sector to play a crucial role in drug innovation. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 3883

    https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-veranova-carbogen-lead-adc-investments-axplora-polfa-tarchomin-famar-expand-european-footprint

    #PharmaFlow by PHARMACOMPASS
    10 Jul 2025
    Share Share
    CDMO Activity Tracker: Bora, PolPharma make acquisitions; Evonik, EUROAPI, Porton announce technological expansions

    CDMO Activity Tracker: Bora, PolPharma make acquisitions; Evonik, EUROAPI, Porton announce technological expansions

    The contract development and manufacturing organization (CDMO) space continued to grow at an impressive pace in the second half (H2) of 2024, with significant progress being made across cell and gene therapies (CGTs), antibody-drug conjugates (ADCs), novel drug modalities, and digital solutions.Some of the key players in the CDMO space include Lonza, EUROAPI, Evonik, SEQENS, Fujifilm Diosynth Biotechnologies, Quotient Sciences, Axplora, PolPharma, and Famar from Europe; Mission CDMO, LGM Pharma, Veranova, and Thermo Fisher from the US; and Samsung Biologics, Bora Pharmaceuticals, and Porton Pharma Solutions from Asia. Texas-based Mission CDMO has been in the pharma industry for over 75 years. Today, it is known for its comprehensive contract services and high-quality manufacturing capabilities that have reinforced its position as a trusted partner. View CDMO Activity Tracker for H2 2024 (Free Excel Available)Bora, PolPharma drive CDMO acquisitions; Samsung Biologics clocks over US$ 4 bn in contract valueThe second half of 2024 saw several high-value acquisitions and expansions that reshaped the CDMO landscape. South Korea-based Samsung Biologics clocked a cumulative contract value of over US$ 4 billion. It signed its largest manufacturing deal with an Asia-based pharmaceutical company, valued at US$ 1.24 billion. It also announced a series of manufacturing deals with a European drugmaker worth over US$ 668 million. Samsung Biologics is also building a dedicated ADC facility that is likely to be complete soon. Taiwan’s largest CDMO, Bora Pharmaceuticals, announced its second acquisition of the year. It bought New Jersey-based Pyros Pharmaceuticals, a developer of rare disease treatments. Pyros recently launched Vigafyde, the only ready-to-use vigabatrin oral solution and the first new product approved to treat infantile spasms in 15 years. Bora also announced a strategic investment in Tanvex Biopharma, thereby creating a global platform for biologics development and supply.PolPharma acquired Ziołolek, a renowned manufacturer of dermatological products, medical devices, and OTC medicines, thereby expanding its product portfolio. It also launched a state-of-the-art HPAPI (highly potent active pharmaceutical ingredients) facility in Poland, which is being seen as another step towards securing Europe’s drug supply chain.In other developments, Avid Bioservices got acquired by funds managed by Ampersand and British healthcare investment firm GHO Capital Partners in an all-cash deal worth US$ 1.1 billion. And Agilent Technologies agreed to acquire Canadian specialty CDMO Biovectra for US$ 925 million, thereby enhancing its capabilities in gene-editing technologies and sterile fill-finish services. View CDMO Activity Tracker for H2 2024 (Free Excel Available) Evonik, EUROAPI, Porton Pharma, GSK announce tieups, technological expansionsSeveral CDMOs announced new collaborations and acquired new capabilities to enhance their service offerings. Evonik expanded its formulation capabilities for lipid nanoparticles used for mRNA and gene therapies through a collaboration with KNAUER Wissenschaftliche Geräte. This partnership aims to expand Evonik’s portfolio of biosolutions.Evonik is also restructuring its keto and pharma amino acid business to focus on strategic core growth areas. Evonik launched Eudracap colon functional capsules for targeted delivery of oral drugs. These ready-to-fill capsules are designed to release their contents specifically in the colon, improving the efficacy of treatments for various gastrointestinal conditions. Evonik also opened a new facility for drying aqueous dispersions of Eudragit polymers in Darmstadt, Germany. This facility will enhance Evonik’s capabilities in producing high-quality polymers for pharmaceutical applications.EUROAPI launched a new AI-powered Electronic Batch Record solution in collaboration with Aizon to enhance manufacturing productivity. This collaboration aims to digitize operations towards more data-driven manufacturing, focusing on small-scale productions and highly flexible plants.Porton Pharma Solutions has expanded its reach through several strategic initiatives. In October, Porton entered into a partnership with Shanghai InnoStar to enhance its service offerings beyond small molecules, targeting peptides, oligonucleotide drugs, conjugated drugs, and advanced therapies. It continued to grow its capabilities by enhancing its GMP manufacturing capacity in Fengxian, Shanghai (China). The facility’s expansion is aimed at increasing the production of novel therapies, including peptides and oligonucleotide drugs. These moves are part of Porton’s broader strategy to position itself at the forefront of advanced pharmaceutical manufacturing.Corden Pharma is investing € 900 million (US$ 985 million) over the next three years to expand its peptide platform facilities in Colorado (US) and Europe. While the US site will help meet the rising demand for GLP-1 peptides, in Europe, CordenPharma will construct a greenfield facility for small to large-scale peptide development and manufacturing.CDMO Touchlight signed a licensing agreement with GSK that grants the drug behemoth non-exclusive rights to use Touchlight’s proprietary enzymatic doggybone DNA (dbDNA) technology for the development and production of mRNA-based products, particularly vaccines. Curia also integrated enzymatic dbDNA solutions through a collaboration with Touchlight, enhancing mRNA production for vaccine and cancer therapies. View CDMO Activity Tracker for H2 2024 (Free Excel Available) Lonza, Merck, Dr. Reddy’s owned Aurigene invest in cell and gene therapiesThe CGT space continued to draw both deals and investments. Lonza and Vertex signed a long-term commercial supply agreement for Casgevy, the world’s first CRISPR/Cas9 gene-edited cell therapy, to treat sickle cell disease and beta thalassemia. This agreement includes manufacturing at Lonza’s Geleen (the Netherlands) cell therapy manufacturing facility, with plans to expand to Portsmouth, New Hampshire (US).Miltenyi Biotec began manufacturing lentiviral vectors for Adaptimmune’s Tecelra, the first engineered TCR T-cell therapy for the rare soft tissue cancer synovial sarcoma approved by the US Food and Drug Administration.Merck KGaA commenced commercial production at its first GMP-compliant manufacturing line for cell culture media (CCM) in China. This facility addresses the growing local demand for quality custom CCM used in biopharmaceuticals, vaccines, and novel therapeutics.Aurigene and Edity Therapeutics announced a strategic collaboration in cell therapy, with Aurigene providing cell therapy discovery services to support Edity’s clinical development. Additionally, Aurigene and its parent, Dr. Reddy’s Laboratories, signed a memorandum of understanding (MoU) with Kainomyx for the development and commercialization of an affordable anti-malarial drug. ProBio and UCI Therapeutics signed an MoU for a comprehensive collaboration in gene delivery technologies, including viral and non-viral approaches. Additionally, Korea’s VaxCell-Bio partnered with ProBio to accelerate the development of its chimeric antigen receptor (CAR)-related therapies.The ADC market continued to be a hotbed of innovation and strategic expansion. Merck KGaA invested € 70 million (US$ 75 million) to triple its ADC manufacturing capacity at its Missouri (US) facility, aiming to support the rising demand for oncology therapies.Sterling Pharma entered into a partnership with GlycoNex to support the clinical trials of their ADCs that target solid tumors. And, NJ Bio and Charles River Laboratories also announced a collaboration to optimize ADC manufacturing.The adeno-associated viral (AAV) vector field also saw activity with Rentschler Biopharma and Forge Biologics announcing the launch of a new service offering and a manufacturing platform, respectively. Similarly, Andelyn Biosciences was selected by Hubble Therapeutics to manufacture clinical grade AAV.Meanwhile, Lonza has gone in for a restructuring exercise in order to become a “pure-play CDMO”. It has exited its capsules and health ingredients business, and adopted a new organizational structure. The Swiss CDMO has also extended a collaboration with a major global biopharmaceutical partner for commercial-scale manufacture of ADCs. View CDMO Activity Tracker for H2 2024 (Free Excel Available) Our viewAs pharmaceutical development becomes increasingly complex, CDMOs are no longer just manufacturing partners, but critical innovation hubs. Little wonder then that 2024’s biggest pharma deal was in the CDMO space – Novo Holdings’ US$ 16.5 billion buyout of Catalent. This trend should gather momentum. We expect more M&A activity in this space in 2025. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 3521

    https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-bora-polpharma-make-acquisitions-evonik-euroapi-porton-announce-technological-expansions

    #PharmaFlow by PHARMACOMPASS
    19 Dec 2024
    Share Share
    DMF filings hit all-time high in Q3 2024; China tops list with 58% increase in Type II submissions

    DMF filings hit all-time high in Q3 2024; China tops list with 58% increase in Type II submissions

    Drug Master Files, or DMFs, are confidential documents that play a crucial role in the pharmaceutical industry. These files, submitted to the US Food and Drug Administration (FDA), contain detailed information about ingredients, manufacturing processes, and packaging of medicines. They help the FDA oversee drug quality. Of the four types, Type II DMFs involve active pharmaceutical ingredients (APIs) for both branded and generic drugs. The third quarter (Q3) of 2024 saw Type II DMF submissions set a new record. A total of 309 Type II DMFs were submitted to the FDA during this period, a substantial 24.6 percent increase over Q3 2023 (with 248 submissions). The second quarter of 2024 too saw a remarkable increase, with 237 Type II DMFs being submitted compared to 178 in Q2 2023. View FDA DMF Filings in Q3 2024 (Power BI Dashboard, Free Excel Available) China witnesses steep rise in DMF submissions, beats India with maximum filings In Q3 2024, China filed 153 DMFs submissions, marking a substantial 57.7 percent increase from the 97 submissions filed in Q3 2023. India maintained its strong position but fell to the number two spot with 110 DMFs, representing a modest 3.8 percent increase from 106 in Q3 2023. The US, which came a distant third, saw a slight decline in DMF submissions, with 13 filed in Q3 2024, as compared to 18 in Q3 2023. For several years, India had a lead in Type II DMFs. Since 2020, which marked the start of the pandemic, we have noticed a gradual increase in DMFs filed by China. This year, China has surpassed India considerably in the first three quarters. During the first nine months of 2024, China submitted 372, while India filed 286 DMFs. If this lead is maintained in Q4, DMFs from China will surpass that of India in 2024.  Amongst European countries, Spain led with seven DMFs, followed by Italy at four, and Germany and the Netherlands at three each. Among other nations, Japan contributed six while Israel submitted four DMFs. In company-wise tally, China’s Jiangsu East-Mab Biomedical Technology topped the list with an impressive 14 DMFs. On its heels were Indian companies — MSN at 13 DMFs, and Vamsi Labs and Hetero Drugs at nine DMFs each. China’s Porton Pharma and Wuxi AppTec filed five, while Shanghai Keze Yongxin Biotechnology, and Qingdao Glycogene Pharmaceutical contributed four submissions each. India's Maithri Drugs also submitted four. Japanese company Santeja filed five. Overall, Asia accounted for nearly 90 percent, with China contributing a dominant 49.5 percent of all DMF submissions. India was at 35.6 percent, the US at 4.2 percent, while Europe contributed 6.5 percent.  View FDA DMF Filings in Q3 2024 (Power BI Dashboard, Free Excel Available) Diabetes, obesity, cancer, women’s health drugs emerge as hot molecules in Q3 2024 In terms of molecules, semaglutide (used for the treatment of type 2 diabetes and weight management) and relugolix (to treat prostate cancer and uterine fibroids) saw six DMF filings each in Q3 2024, indicating significant industry interest in these compounds. Following closely behind were semaglutide’s competitor tirzepatide and overactive bladder therapy vibegron, garnering four DMFs each. Finerenone (a non-steroidal drug for chronic kidney disease associated with type 2 diabetes) and voclosporin (an immunosuppressant for lupus nephritis) saw three DMFs each.  The last quarter also witnessed the introduction of 14 molecules with first-time DMFs. Among them were acetoxy empagliflozin, cabozantinib fumarate, tivozanib hydrochloride monohydrate, diosmetin, trilaciclib, clenbuterol hydrochloride, fenoterol hydrobromide, tapinarof and fezolinetant. Fezolinetant, with a DMF from Spain’s Moehs Iberica, is the active ingredient in Astellas’ Veozah, which is the first non-hormonal treatment for menopausal symptoms approved by the FDA. Tapinarof, filed by India’s Maithri Drugs, is used in Vtama, a novel steroid-free psoriasis cream. Other compounds that made their DMF debut include berotralstat, calcium phosphoryl choline chloride, phloroglucinol dihydrate, belumosudil mesylate and trimethylphloroglucinol. During Q2 2024, there were 19 drugs that saw DMF submissions for the first time, including molecules like triptorelin, sorafenib, pralsetinib, trilaciclib dihydrochloride, resmetirom (hepatology) and teneligliptin hydrochloride hydrate (metabolic disorders).  View FDA DMF Filings in Q3 2024 (Power BI Dashboard, Free Excel Available)    GDUFA fee for FY 2025: The FDA’s Generic Drug User Fee Amendments (GDUFA) is a law designed to speed access to safe and effective generic drugs to the public and reduce costs to the industry. The fiscal year 2025 fee rates were published on July 31, 2024. The FDA has revised fees under GDUFA III for all categories. While there is a slight increase in the DMF fee from US$ 94,682 in 2024 to US$ 95,084 in 2025, the ANDA fee has witnessed a significant jump — from US$ 252,453 in 2024 to US$ 321,920 in 2025. FY 2024 and FY 2025 User Fee Rates Generic drug fee category Fees rates for FY 2024 Fees rates for FY 2025 Applications: Abbreviated New Drug Application (ANDA) US$ 2,52,453   US$ 3,21,920   Drug Master File (DMF) US$ 94,682 US$ 95,084 Facilities: Active Pharmaceutical Ingredient (API)—Domestic US$ 40,464 US$ 41,580 API—Foreign US$ 55,464 US$ 56,580 Finished Dosage Form (FDF)—Domestic US$ 2,20,427   US$ 2,31,952 FDF—Foreign US$ 2,35,427   US$ 2,46,952 Contract Manufacturing Organization (CMO)—Domestic US$ 52,902 US$ 55,668 CMO—Foreign US$ 67,902 US$ 70,668 GDUFA Program: Large size operation generic drug applicant US$ 17,29,629   US$ 18,91,664 Medium size operation generic drug applicant US$ 6,91,852   US$ 7,56,666 Small business generic drug applicant US$ 1,72,963   US$ 1,89,166 Our view The highlight of the last few quarters has been the sharp rise in Type II DMF filings from China. The submission of a DMF is not required by law or any FDA regulation. FDA’s DMF guideline offers guidance on acceptable approaches to meeting regulatory requirements. Moreover, DMFs establish trust in APIs from lesser-known companies. With a growing emphasis on compliance and quality assurance, it appears that Chinese drug companies are eager to demonstrate their commitment to high standards and build trust in the US market. And that’s good news for the pharmaceutical industry.   
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 7971

    https://www.pharmacompass.com/radio-compass-blog/dmf-filings-hit-all-time-high-in-q3-2024-china-tops-list-with-58-increase-in-type-ii-submissions

    #PharmaFlow by PHARMACOMPASS
    24 Oct 2024
    Share Share
    CDMO Activity Tracker: Novo’s parent buys Catalent for US$ 16.5 bn; Fujifilm, Merck KGaA, Axplora expand capabilities

    CDMO Activity Tracker: Novo’s parent buys Catalent for US$ 16.5 bn; Fujifilm, Merck KGaA, Axplora expand capabilities

    During the first half (H1) of 2024, the global contract development and manufacturing organization (CDMO) landscape was driven by the escalating demand for complex drug development and manufacturing.With the industry grappling with constantly evolving therapeutic modalities, CDMOs are racing to invest in cutting-edge technologies and infrastructure to meet the growing needs of pharmaceutical and biotech companies.Some of the key players in the CDMO space are Catalent, EUROAPI, Lonza, Axplora, Thermo Fisher, SEQENS, Samsung Biologics, Fujifilm Diosynth Biotechnologies, Quotient Sciences, Famar, LGM Pharma, Veranova, and Evonik. View CDMO Activity Tracker for H1 2024 (Free Excel Available)Novo’s parent buys Catalent for US$ 16.5 bn; Bora, Lonza, Siegfried expand US footprintDuring H1 2024, several European and Asian drugmakers expanded their footprints in the US. In February, Novo Nordisk’s parent company, the Novo Nordisk Foundation, announced the acquisition of Catalent through its investment arm Novo Holdings for US$ 16.5 billion. Novo Holdings plans to sell three of Catalent’s “fill-finish” sites to Novo Nordisk for US$ 11 billion. The deal is expected to allow the Danish drugmaker “to serve significantly more people living with diabetes and obesity,” a company statement said.Taiwan-headquartered Bora Pharmaceuticals forged ahead with its expansion plans in the US market by acquiring Minnesota-based generics manufacturer Upsher-Smith Laboratories. Emergent BioSolutions said it is selling its Maryland facility to an affiliate of Bora. This site in Camden is part of its CDMO, Emergent Bioservices, and offers clinical and commercial non-viral aseptic fill/finish services on four fill lines, including lyophilization, formulation development, and support services.Swiss drugmaker Lonza has agreed to acquire Genentech’s manufacturing facility in California, US, from Roche for US$ 1.2 billion in cash. The site, located in the city of Vacaville, is one of the largest biologics manufacturing facilities in the world by volume.Lonza also launched an artificial intelligence-driven route design technology for choosing the optimal synthetic pathway to manufacture novel APIs.Switzerland’s Siegfried is acquiring a Wisconsin (US)-based CDMO that specializes in early-phase development and manufacturing services from Curia Global to strengthen its capabilities in North America. Siegfried will further develop the site into its North American Siegfried Acceleration Hub for early-phase CDMO services. View CDMO Activity Tracker for H1 2024 (Free Excel Available) Merck Millipore, SK Bioscience lead CGT boom; Fujifilm, Axplora, expand CDMO capabilitiesThe burgeoning field of cell and gene therapies (CGTs) is driving significant investments in CDMOs. CGTs saw considerable deal-making too. Merck KGaA agreed to buy Wisconsin-based Mirus Bio for US$ 600 million. Mirus Bio is a specialist in the development and commercialization of transfection reagents that are used to help introduce genetic material into cells. These reagents play a key role in the production of viral vectors for CGTs.Similarly, South Korea’s SK Bioscience acquired a 60 percent stake in IDT Biologika GmbH for KRW 339 billion (US$ 244 million). IDT Biologika is a 104-year-old German company that ranks among the top 10 vaccine producers in the world.CDMOs are also expanding their capabilities in order to lead innovation for their pharmaceutical partners. Fujifilm Diosynth Biotechnologies is investing US$ 1.2 billion in its large-scale cell culture CDMO business to further expand its end-to-end bio-manufacturing facility in North Carolina, bringing the total investment in the facility to over US$ 3.2 billion. Similarly, Merck KGaA owned MilliporeSigma made its biggest investment in the Asia-Pacific region in March when it invested € 300 million (US$ 327 million) in a new bioprocessing production center in Daejeon, South Korea.German CDMO giant Axplora is investing € 8 million (US$ 8.73 million) to expand capacity for antibody drug conjugate (ADC) payload manufacturing at its Le Mans site in France. Catalent completed upgrades to its capsule filling capabilities of dry powders for inhalation to handle potent drugs at its Boston facility. This now positions Catalent as the CDMO with the largest GMP capacity for capsule spray-dried and carrier-based inhaled powders.LGM Pharma increased its Analytical Testing Services (ATS) by 50 percent with a US$ 2 million investment and introduced new suppository manufacturing capabilities to its CDMO portfolio. Minakem has invested in a new production unit in Montreal, Canada, for steroid APIs. View CDMO Activity Tracker for H1 2024 (Free Excel Available) EUROAPI kicks off four-year sweeping plan; LegoChem partners Samsung Biologics for ADC programSanofi’s spinoff EUROAPI marked 2024 as a “transition year”, setting in motion its Focus-27 plan for profitable growth in the future. The sweeping four-year plan includes a streamlined value-added portfolio focused on highly differentiated and profitable APIs, and a CDMO focused on late-stage and high-value complex small molecules and tides supported by unique technological platforms. The leading French small molecules player signed a five-year collaboration with Ireland’s Priothera wherein EUROAPI will develop and industrialize the manufacturing process of an innovative, complex molecule for blood cancers – mocravimod. The project will be carried out at EUROAPI’s site in Budapest, which is its center of excellence for complex chemistry.South Korea’s CDMO powerhouse Samsung Biologics has partnered LegoChem Biosciences and will provide antibody development and drug substance manufacturing services as a part of LegoChem’s ADC program designed to treat solid tumors. LegoChem aims to submit an investigational new drug application to the US Food and Drug Administration (FDA) in the first half of 2025. Aurigene and Vipergen have joined forces to offer DNA-encoded library (DEL) screening for drug discovery. By combining Aurigene’s drug discovery capabilities with Vipergen’s DEL screening technologies, they seek to create a powerful tool that can quickly test over a billion small-molecule compounds against different disease targets. Dr. Reddy’s Laboratories’ company Aurigene also inaugurated its biologics facility spread across 70,000 square feet.Chinese biotech startup Pleryon is collaborating with France’s SEQENS, a leader in specialty ingredients, to develop and manufacture the former’s lead candidate, an innovative polymer to treat osteoarthritis. Famar is collaborating with Lavipharm and will serve as the contract manufacturer for the latter’s recently added analgesic pharmaceutical products — Lonarid N and Lonalgal. View CDMO Activity Tracker for H1 2024 (Free Excel Available) Our view Key trends observed in H1 2024 include a surge in investments for fill-finish facilities, a growing emphasis on cell and gene therapies, and advancements in ADC manufacturing. With the proliferation of these new classes of drugs, the CDMO space has been rapidly changing in recent years. In the future, the integration of digital technologies, such as AI and automation, will be a key differentiator for CDMOs looking to optimize their operations and accelerate drug development timelines. 
    subscribeSubscribe
    ExcelExcel Download

    Impressions: 4118

    https://www.pharmacompass.com/radio-compass-blog/cdmo-activity-tracker-novo-s-parent-buys-catalent-for-us-16-5-bn-fujifilm-merck-kgaa-axplora-lonza-expand-capabilities

    #PharmaFlow by PHARMACOMPASS
    08 Aug 2024
    Share Share

    NEWS #PharmaBuzz

    read-more
    read-more
    Cohance Lifesciences to sell CR Bio assets to Chromo Laboratories
    Cohance Lifesciences to sell CR Bio assets to Chromo Laboratories

    23 Jun 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/news/cohance-lifesciences-to-sell-cr-bio-assets-to-chromo-laboratories-india-for-rs-16-cr-17298

    INDPHARMAPOST
    23 Jun 2025
    Share Share
    Suven Pharmaceuticals is now Cohance Lifesciences
    Suven Pharmaceuticals is now Cohance Lifesciences

    09 May 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/news/suven-pharmaceuticals-is-now-cohance-lifesciences-17129

    INDPHARMAPOST
    09 May 2025
    Share Share
    Suven Pharma Sets May 1 As Effective Date For Cohance Merger
    Suven Pharma Sets May 1 As Effective Date For Cohance Merger

    25 Apr 2025

    // PRESS RELEASE

    https://www.suvenpharm.com/pdf/Investors/ShareHoldersInfo/Stock%20Exchange%20Communications/SuvenPharma_PressRelease25042025.pdf

    PRESS RELEASE
    25 Apr 2025
    Share Share
    NCLT approves amalgamation of Cohance with Suven Pharma
    NCLT approves amalgamation of Cohance with Suven Pharma

    02 Apr 2025

    // INDPHARMAPOST

    https://www.indianpharmapost.com/news/nclt-approves-amalgamation-of-cohance-lifesciences-into-and-with-suven-pharmaceuticals-16958

    INDPHARMAPOST
    02 Apr 2025
    Share Share
    Suven, Cohance to Double Business Revenue to Rs 6,000 Cr by FY29
    Suven, Cohance to Double Business Revenue to Rs 6,000 Cr by FY29

    01 Nov 2024

    // ECONOMICTIMES

    https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/suven-cohance-aim-to-double-combined-business-revenue-to-rs-6000-cr-by-fy29/articleshow/114845104.cms

    ECONOMICTIMES
    01 Nov 2024
    Share Share
    Cohance Lifesciences merger with Suven Pharma gets NSE, BSE nod
    Cohance Lifesciences merger with Suven Pharma gets NSE, BSE nod

    27 Jul 2024

    // TIMESOFINDIA

    https://timesofindia.indiatimes.com/business/india-business/cohance-lifesciences-merger-with-suven-pharma-gets-nse-bse-nod/articleshow/112068320.cms

    TIMESOFINDIA
    27 Jul 2024
    Share Share

    ALL APIs

    read-moreClick the button for full data set
    read-moreClick the button for full data set

    01

    Rivaroxaban

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    BIO Asia-Taiwan
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothCohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
    USDMF arrow-down Click Us! arrow-down
    ✖

    GDUFA

    DMF Review : N/A

    Rev. Date :

    Pay. Date :

    DMF Number : 32115

    Submission : 2017-10-02

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : CEP 2020-274 - Rev 02

    Issue Date : 2024-06-28

    Type : Chemical

    Substance Number : 2932

    Status : Valid

     JDMF arrow-down
    ✖

    Registration Number : 304MF10154

    Registrant's Address : 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala MIDC, Chakala, Andheri East, Mumbai-400 093 Maharash

    Initial Date of Registration : 2022-12-07

    Latest Date of Registration :

    EU-WCInactive-api
    ✖

    Date of Issue : 2022-08-25

    Valid Till : 2025-02-07

    Written Confirmation Number : WC-0195

    Address of the Firm :

    NDC arrow-down
    ✖

    NDC Package Code : 76072-1008

    Start Marketing Date : 2017-06-05

    End Marketing Date : 2025-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    KDMF arrow-down
    ✖

    Registrant Name : M-Peak Korea Co., Ltd.

    Registration Date : 2023-12-11

    Registration Number : Number 812-22-ND

    Manufacturer Name : ZCL Chemicals Limited

    Manufacturer Address : Plot No. 3102/B GIDC, Industrial Estate Ankleshwar-393 002, Dist. Bharuch, Gujarat state, India

     VMF ASMF, CN... arrow-down
    ✖
    Available Reg. Filing : ASMF, CN, BR
    AUDIT
    Cohance

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    02

    Aripiprazole

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    BIO Asia-Taiwan
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothCohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2017-11-16

    Pay. Date : 2017-10-18

    DMF Number : 30120

    Submission : 2015-12-14

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : CEP 2016-021 - Rev 02

    Issue Date : 2024-07-09

    Type : Chemical

    Substance Number : 2617

    Status : Valid

     JDMF EU-WCInactive-api
    ✖

    Date of Issue : 2022-08-25

    Valid Till : 2025-02-07

    Written Confirmation Number : WC-0195

    Address of the Firm :

    NDC arrow-down
    ✖

    NDC Package Code : 76072-1002

    Start Marketing Date : 2016-04-01

    End Marketing Date : 2025-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    KDMF arrow-down
    ✖

    Registrant Name : Hwail Pharmaceutical Co., Ltd.

    Registration Date : 2018-03-16

    Registration Number : 20180316-209-J-68

    Manufacturer Name : Cohance Lifesciences Limited

    Manufacturer Address : API Unit-Ⅲ, Plot No. 3102/B GIDC, Industrial Estate Ankleshwar-393 002, Dist. Bharuch, Gujarat state, India

     VMF Others AUDIT
    Cohance

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    03

    Atomoxetin Hydrochloride

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    BIO Asia-Taiwan
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothCohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2019-12-27

    Pay. Date : 2019-12-03

    DMF Number : 29211

    Submission : 2015-03-26

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : CEP 2015-150 - Rev 01

    Issue Date : 2024-07-09

    Type : Chemical

    Substance Number : 2640

    Status : Valid

     JDMF EU-WCInactive-api
    ✖

    Date of Issue : 2022-08-25

    Valid Till : 2025-02-07

    Written Confirmation Number : WC-0195

    Address of the Firm :

    NDC arrow-down
    ✖

    NDC Package Code : 76072-1011

    Start Marketing Date : 2017-06-05

    End Marketing Date : 2025-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    KDMF VMF CN, RU, ... arrow-down
    ✖
    Available Reg. Filing : CN, RU, TDMF, CA
    AUDIT
    Cohance

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    04

    Dipyridamole

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    BIO Asia-Taiwan
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothCohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2016-05-18

    Pay. Date : 2015-09-29

    DMF Number : 29745

    Submission : 2015-09-04

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 2014-148 - Rev 01

    Issue Date : 2022-12-16

    Type : Chemical

    Substance Number : 1199

    Status : Valid

     JDMF EU-WCInactive-api
    ✖

    Date of Issue : 2022-07-07

    Valid Till : 2025-07-21

    Written Confirmation Number : WC-0150

    Address of the Firm :

    NDC arrow-down
    ✖

    NDC Package Code : 17511-122

    Start Marketing Date : 2020-01-20

    End Marketing Date : 2026-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT FOR ...

    KDMF VMF CN, RU, ... arrow-down
    ✖
    Available Reg. Filing : CN, RU, CA, SA, AU
    AUDIT
    Cohance

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    05

    Doxazosin Mesylate

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    BIO Asia-Taiwan
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothCohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2019-12-31

    Pay. Date : 2019-12-23

    DMF Number : 22941

    Submission : 2009-07-10

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : CEP 2010-312 - Rev 03

    Issue Date : 2023-10-27

    Type : Chemical

    Substance Number : 2125

    Status : Valid

     JDMF EU-WCInactive-api
    ✖

    Date of Issue : 2022-07-07

    Valid Till : 2025-07-21

    Written Confirmation Number : WC-0150

    Address of the Firm :

    NDC arrow-down
    ✖

    NDC Package Code : 17511-113

    Start Marketing Date : 2009-07-31

    End Marketing Date : 2026-12-31

    Dosage Form (Strength) : POWDER (25kg/25kg)

    Marketing Category : BULK INGREDIENT FOR ...

    KDMF VMF BR, RU arrow-down
    ✖
    Available Reg. Filing : BR, RU
    AUDIT
    Cohance

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    06

    Entacapone

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    BIO Asia-Taiwan
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothCohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2016-05-24

    Pay. Date : 2015-09-29

    DMF Number : 23937

    Submission : 2010-06-30

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 2010-337 - Rev 03

    Issue Date : 2022-12-15

    Type : Chemical

    Substance Number : 2574

    Status : Valid

     JDMF EU-WCInactive-api
    ✖

    Date of Issue : 2022-07-07

    Valid Till : 2025-07-21

    Written Confirmation Number : WC-0150

    Address of the Firm :

    NDC arrow-down
    ✖

    NDC Package Code : 17511-109

    Start Marketing Date : 2010-07-30

    End Marketing Date : 2026-12-31

    Dosage Form (Strength) : POWDER (25kg/25kg)

    Marketing Category : BULK INGREDIENT FOR ...

    KDMF arrow-down
    ✖

    Registrant Name : Kukjeon Pharmaceutical Co., Ltd.

    Registration Date : 2019-03-20

    Registration Number : 20190320-209-J-208

    Manufacturer Name : Cohance Lifesciences Limited

    Manufacturer Address : RS 50/1, Mukteswarapuram Village, Jaggaiahpeta Mandal, NTR District-521 457, Andhra Pradesh, India

     VMF CN, BR, ... arrow-down
    ✖
    Available Reg. Filing : CN, BR, RU, TDMF
    AUDIT
    Cohance

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    07

    Fluvoxamine

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    BIO Asia-Taiwan
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothCohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2018-01-04

    Pay. Date : 2017-10-18

    DMF Number : 29582

    Submission : 2015-07-22

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : CEP 2014-089 - Rev 04

    Issue Date : 2024-09-27

    Type : Chemical

    Substance Number : 1977

    Status : Valid

     JDMF EU-WCInactive-api
    ✖

    Date of Issue : 2022-08-25

    Valid Till : 2025-02-07

    Written Confirmation Number : WC-0195

    Address of the Firm :

    NDC arrow-down
    ✖

    NDC Package Code : 76072-1003

    Start Marketing Date : 2016-04-01

    End Marketing Date : 2025-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    KDMF VMF TDMF arrow-down
    ✖
    Available Reg. Filing : TDMF
    AUDIT
    Cohance

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    08

    Lamotrigine

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    BIO Asia-Taiwan
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothCohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2013-08-29

    Pay. Date : 2013-03-20

    DMF Number : 23251

    Submission : 2009-11-04

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R0-CEP 2022-417 - Rev 00

    Issue Date : 2022-12-15

    Type : Chemical

    Substance Number : 1756

    Status : Valid

     JDMF EU-WCInactive-api
    ✖

    Date of Issue : 2022-07-07

    Valid Till : 2025-07-21

    Written Confirmation Number : WC-0150

    Address of the Firm :

    NDC arrow-down
    ✖

    NDC Package Code : 17511-103

    Start Marketing Date : 2022-02-14

    End Marketing Date : 2026-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    KDMF arrow-down
    ✖

    Registrant Name : Wonpung Pharmaceutical Co., Ltd.

    Registration Date : 2022-12-12

    Registration Number : 20220112-209-J-1158(A)

    Manufacturer Name : Cohance Lifescience Limited

    Manufacturer Address : API Unit-I, RS 50/1, Mukteswarapuram Village, Jaggaiahpet Mandal, NTR District – 521 457, Andhra Pradesh, India

     VMF CN, BR, ... arrow-down
    ✖
    Available Reg. Filing : CN, BR, RU, CA
    AUDIT
    Cohance

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    09

    Midazolam

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    BIO Asia-Taiwan
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothCohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2015-09-03

    Pay. Date : 2015-02-12

    DMF Number : 26871

    Submission : 2013-02-04

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 2010-141 - Rev 02

    Issue Date : 2022-12-15

    Type : Chemical

    Substance Number : 936

    Status : Valid

     JDMF EU-WCInactive-api
    ✖

    Date of Issue : 2022-07-07

    Valid Till : 2025-07-21

    Written Confirmation Number : WC-0150

    Address of the Firm :

    NDC arrow-down
    ✖

    NDC Package Code : 17511-115

    Start Marketing Date : 2020-01-17

    End Marketing Date : 2026-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    KDMF arrow-down
    ✖

    Registrant Name : Kukjeon Pharmaceutical Co., Ltd.

    Registration Date : 2021-03-25

    Registration Number : 20210325-210-J-815

    Manufacturer Name : Cohance Lifesciences Limited

    Manufacturer Address : RS 50/1, Mukteswarapuram Village, Jaggaiahpeta Mandal, NTR District-521 457, Andhra Pradesh, India

     VMF BR, TDMF... arrow-down
    ✖
    Available Reg. Filing : BR, TDMF, SA, KE
    AUDIT
    Cohance

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    10

    Tamsulosin

    India

    USDMF, CEP/COS, JDMF, EU-WC, NDC, KDMF, VMF, Others

    arrow
    BIO Asia-Taiwan
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual BoothCohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.
    USDMF arrow-down
    ✖

    GDUFA

    DMF Review : Reviewed

    Rev. Date : 2015-12-23

    Pay. Date : 2015-08-27

    DMF Number : 28648

    Submission : 2014-09-15

    Status : Active

    Type : II

     CEP/COS arrow-down
    ✖

    Certificate Number : R1-CEP 2012-309 - Rev 02

    Issue Date : 2022-12-15

    Type : Chemical

    Substance Number : 2131

    Status : Valid

     JDMF EU-WCInactive-api
    ✖

    Date of Issue : 2022-07-07

    Valid Till : 2025-07-21

    Written Confirmation Number : WC-0150

    Address of the Firm :

    NDC arrow-down
    ✖

    NDC Package Code : 17511-118

    Start Marketing Date : 2020-01-20

    End Marketing Date : 2026-12-31

    Dosage Form (Strength) : POWDER (1kg/kg)

    Marketing Category : BULK INGREDIENT

    KDMF VMF CN, BR, ... arrow-down
    ✖
    Available Reg. Filing : CN, BR, TDMF, SA, KE
    AUDIT
    Cohance

    Product
    Web Link

    Stock Recap
    #PipelineProspector

    Market
    Place

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    KEY PRODUCTS

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Sponsored Ads.
    full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view
    Sponsored Ads.full-view

    Services

    Discover the service capabilities from this company

    Clinical Trials

    Discover their expertise for : Clinical Trials

    API Manufacturing

    Discover their expertise for : API Manufacturing

    API & Drug Product Development

    Discover their expertise for : API & Drug Product Development

    KEY SERVICES

    read-more
    read-more

    TOP RANKED SUPPLIER FOR:

    Cohance Lifesciences full-view
    Antibody-Drug Conjugate (ADC) Development
    full-view
    End-to-end CDMO for ADCs
    full-view

    Inspections and registrations

    Check the inspections & registration from this company

    ABOUT THIS PAGE

    Contact Cohance Lifesciences and get a quotation

    Cohance Lifesciences is a supplier offers 82 products (APIs, Excipients or Intermediates).

    Find a price of Rivaroxaban bulk with DMF, CEP, JDMF offered by Cohance Lifesciences

    Find a price of Aripiprazole bulk with DMF, CEP offered by Cohance Lifesciences

    Find a price of Atomoxetin Hydrochloride bulk with DMF, CEP offered by Cohance Lifesciences

    Find a price of Baclofen bulk with DMF, CEP offered by Cohance Lifesciences

    Find a price of Dipyridamole bulk with DMF, CEP offered by Cohance Lifesciences

    Find a price of Doxazosin Mesylate bulk with DMF, CEP offered by Cohance Lifesciences

    Find a price of Entacapone bulk with DMF, CEP offered by Cohance Lifesciences

    Find a price of Flurbiprofen bulk with DMF, CEP offered by Cohance Lifesciences

    Find a price of Fluvoxamine bulk with DMF, CEP offered by Cohance Lifesciences

    Find a price of Lamotrigine bulk with DMF, CEP offered by Cohance Lifesciences

    Find a price of Midazolam bulk with DMF, CEP offered by Cohance Lifesciences

    Find a price of Pirfenidone bulk with DMF, CEP offered by Cohance Lifesciences

    Find a price of Quetiapine Hemifumarate bulk with DMF, CEP offered by Cohance Lifesciences

    Find a price of Tamsulosin bulk with DMF, CEP offered by Cohance Lifesciences

    Find a price of Venlafaxine Hydrochloride bulk with DMF, CEP offered by Cohance Lifesciences

    Find a price of Verapamil Hydrochloride bulk with DMF, CEP offered by Cohance Lifesciences

    Find a price of Zonisamide bulk with DMF, JDMF offered by Cohance Lifesciences

    Find a price of Articaine Hydrochloride bulk with CEP offered by Cohance Lifesciences

    Find a price of Betahistine Dihydrochloride bulk with CEP offered by Cohance Lifesciences

    Find a price of Dapagliflozin Propanediol Monohydrate bulk with DMF offered by Cohance Lifesciences

    Find a price of Diflunisal bulk with DMF offered by Cohance Lifesciences

    Find a price of Hydralazine Hydrochloride bulk with DMF offered by Cohance Lifesciences

    Find a price of Levomepromazine Maleate bulk with CEP offered by Cohance Lifesciences

    Find a price of Lurasidone Hydrochloride bulk with DMF offered by Cohance Lifesciences

    Find a price of Mebeverine bulk with CEP offered by Cohance Lifesciences

    Find a price of Methylphenidate Hydrochloride bulk with CEP offered by Cohance Lifesciences

    Find a price of Mexiletine bulk with DMF offered by Cohance Lifesciences

    Find a price of Posaconazole bulk with DMF offered by Cohance Lifesciences

    Find a price of Ticagrelor bulk with DMF offered by Cohance Lifesciences

    Find a price of Zonisamide bulk with DMF offered by Cohance Lifesciences

    Find a price of 7-Ethyl-10-Hydroxycamptothecin bulk with DMF offered by Cohance Lifesciences

    Find a price of Atomoxetin Hydrochloride bulk with CEP offered by Cohance Lifesciences

    Find a price of Benserazide Hydrochloride bulk with CEP offered by Cohance Lifesciences

    Find a price of Irinotecan Hydrochloride bulk with CEP offered by Cohance Lifesciences

    Find a price of Lamotrigine bulk with CEP offered by Cohance Lifesciences

    Find a price of Levodropropizine bulk with CEP offered by Cohance Lifesciences

    Find a price of Maraviroc bulk with DMF offered by Cohance Lifesciences

    Find a price of Mirabegron bulk with DMF offered by Cohance Lifesciences

    Find a price of Tolcapone bulk with DMF offered by Cohance Lifesciences

    Find a price of Doxazosin Mesylate bulk offered by Cohance Lifesciences

    Find a price of Drotaverine bulk offered by Cohance Lifesciences

    Find a price of Flurbiprofen bulk offered by Cohance Lifesciences

    Find a price of Levomepromazine Maleate bulk offered by Cohance Lifesciences

    Find a price of Mebeverine bulk offered by Cohance Lifesciences

    Find a price of Midazolam bulk offered by Cohance Lifesciences

    Find a price of Midazolam Hydrochloride bulk offered by Cohance Lifesciences

    Find a price of Tapentadol Phosphate bulk offered by Cohance Lifesciences

    Find a price of Venlafaxine Hydrochloride bulk offered by Cohance Lifesciences

    Find a price of Articaine Hydrochloride bulk offered by Cohance Lifesciences

    Find a price of Belotecan bulk offered by Cohance Lifesciences

    Find a price of Bempedoic Acid bulk offered by Cohance Lifesciences

    Find a price of Buspirone bulk offered by Cohance Lifesciences

    Find a price of Cannabidiol bulk offered by Cohance Lifesciences

    Find a price of Cilostazol bulk offered by Cohance Lifesciences

    Find a price of Dabigatran Etexilate Mesylate bulk offered by Cohance Lifesciences

    Find a price of Desvenlafaxine Succinate bulk offered by Cohance Lifesciences

    Find a price of Dexmethylphenidate bulk offered by Cohance Lifesciences

    Find a price of Edoxaban Tosylate bulk offered by Cohance Lifesciences

    Find a price of Exatecan bulk offered by Cohance Lifesciences

    Find a price of Hydroxyzine Pamoate bulk offered by Cohance Lifesciences

    Find a price of Lenalidomide bulk offered by Cohance Lifesciences

    Find a price of Lercanidipine bulk offered by Cohance Lifesciences

    Find a price of Lisdexamfetamine Dimesylate bulk offered by Cohance Lifesciences

    Find a price of Loxoprofen Sodium bulk offered by Cohance Lifesciences

    Find a price of Midazolam Maleate bulk offered by Cohance Lifesciences

    Find a price of Mirabegron bulk offered by Cohance Lifesciences

    Find a price of Monomethyl Auristatin E bulk offered by Cohance Lifesciences

    Find a price of Monomethyl Auristatin F bulk offered by Cohance Lifesciences

    Find a price of Oxolamine Citrate bulk offered by Cohance Lifesciences

    Find a price of Oxolamine Phosphate bulk offered by Cohance Lifesciences

    Find a price of Oxymetazoline Hydrochloride bulk offered by Cohance Lifesciences

    Find a price of Pyridostigmine bulk offered by Cohance Lifesciences

    Find a price of Ractopamine Hydrochloride bulk offered by Cohance Lifesciences

    Find a price of Remimazolam Besylate bulk offered by Cohance Lifesciences

    Find a price of Rubitecan bulk offered by Cohance Lifesciences

    Find a price of Silatecan bulk offered by Cohance Lifesciences

    Find a price of SN-22 bulk offered by Cohance Lifesciences

    Find a price of Topotecan Hydrochloride bulk offered by Cohance Lifesciences

    Find a price of Trimebutine Maleate bulk offered by Cohance Lifesciences

    Find a price of Trimetazidine Hydrochloride bulk offered by Cohance Lifesciences

    Find a price of Verapamil bulk offered by Cohance Lifesciences

    Find a price of Zilpaterol HCl bulk offered by Cohance Lifesciences

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search